Citation Impact
Citing Papers
Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
2012
The Presumed Hyporesponsive Behavior of Rheumatoid Arthritis T Lymphocytes Can Be Attributed to Spontaneous Ex Vivo Apoptosis rather than Defects in T Cell Receptor Signaling
2009
Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis
2018 StandoutNobel
Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment
2010
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
2014
Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines
2013
Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
2013
Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis
2013
Rheumatoid arthritis
2018 Standout
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
2010
Rheumatoid arthritis
2009
Promising bone-related therapeutic targets for rheumatoid arthritis
2009
Rheumatoid arthritis
2016 Standout
Synovial Tissue Inflammation Mediated by Autoimmune T Cells
2019 StandoutNobel
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study
2010
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
2009
TFOS DEWS II Diagnostic Methodology report
2017 Standout
Abatacept in the treatment of patients with psoriatic arthritis: Results of a six‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II trial
2010
Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation
2011 StandoutNobel
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
2009
How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
2014
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial
2011
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
2015 Standout
Incorporating the Treat-to-Target Concept in Rheumatoid Arthritis
2012
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
2010
Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study
2009
Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
2008
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
2012
Molecular mechanisms of T cell co-stimulation and co-inhibition
2013 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Type 1 diabetes
2013 Standout
Dysbiosis of the gut microbiota in disease
2015 Standout
Rheumatoid arthritis
2010 Standout
Baricitinib in Patients with Refractory Rheumatoid Arthritis
2016
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center study
2011
Abatacept for Rheumatoid Arthritis: A Cochrane Systematic Review
2010
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
2018
Efficacy, pharmacodynamics, and safety of VX‐702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double‐blind, placebo‐controlled clinical studies
2009
Pharmacological Properties and Molecular Mechanisms of Thymol: Prospects for Its Therapeutic Potential and Pharmaceutical Development
2017 Standout
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis
2009 Standout
Nrf2 activation improves experimental rheumatoid arthritis
2023 StandoutNobel
T‐cell receptor signaling and the pathogenesis of autoimmune arthritis: insights from mouse and man
2012 StandoutNobel
Clinically Important Changes in Short Form 36 Health Survey Scales for Use in Rheumatoid Arthritis Clinical Trials: The Impact of Low Responsiveness
2014
Psoriasis Pathogenesis and Treatment
2019 Standout
Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
2010
The clinical utility of inhibiting CD28‐mediated costimulation
2009
Inflammation in dry eye associated with rheumatoid arthritis: Cytokine and in vivo confocal microscopy study
2013
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
2020
A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
2014
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
2013 Standout
Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
2017
VX‐509 (Decernotinib), an Oral Selective JAK‐3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
2015
Impaired T cell receptor signaling and development of T cell–mediated autoimmune arthritis
2020 StandoutNobel
Works of J. Teng being referenced
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
2007
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
2007
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
2008
Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate
2011